tooluniverse-precision-oncology

# Precision Oncology Treatment Advisor Provide actionable treatment recommendations for cancer patients based on their molecular profile using CIViC, ClinVar, OpenTargets, ClinicalTrials.gov, and structure-based analysis. ## Domain Reasoning Treatment selection follows a strict evidence hierarchy: FDA-approved for this specific mutation in this cancer type ranks highest, followed by approval for this mutation in any cancer (tumor-agnostic), then active clinical trials, and finally off-label use. Skipping this hierarchy to recommend off-label therapies when an approved option exists is a clinical error. Always check current NCCN guidelines and recent literature, as approvals change rapidly — a drug that was investigational last year may now be first-line. When looking up treatment for a specific mutation, search CIViC and OncoKB FIRST, not PubMed. These databases have curated evidence levels. PubMed is for when curated databases don't have the answer. ## Treatment Selection Reasoning **Biomarker-to-drug logic** — When a biomarker is identified, the first-line targeted therapy follows established mappings. Always verify current approval status via OncoKB/CIViC, but use this as a starting framework: - **NSCLC**: EGFR exon 19 del / L858R → osimertinib (1L); ALK fusion → alectinib/lorlatinib; ROS1 fusion → crizotinib/entrectinib; KRAS G12C → sotorasib/adagrasib; MET exon 14 skip → capmatinib/tepotinib; RET fusion → selpercatinib; BRAF V600E → dabrafenib+trametinib; NTRK fusi...